Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1489

Shown on this page

Current sort

Live official records

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Interventions: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Andrew Yee, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Essential Thrombocythemia
Interventions: INCA033989, Best Available Treatment; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 35 more

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions: Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2034
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Endometrial Cancer
Interventions: Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation; Radiation · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 77
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 61 more

Conditions: Atrial Fibrillation
Interventions: AFSW Guided DOAC, Continuous DOAC therapy; Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 5,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 93
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more

Conditions: Breast Cancer
Interventions: LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 12 more

Conditions: Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, Locally Advanced Unresectable Hepatocellular Carcinoma
Interventions: TYRA-430; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 6 more

Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2034
U.S. locations: 86
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Immunoglobulin A Nephropathy (IgAN)
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Live official records

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Fabry Disease Registry & Pregnancy Sub-registry

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

CHAMPION-AF Clinical Trial

About this Massachusetts General Hospital institution page